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Type I and II DNA topoisomerases are the targets for numerous clinically
efficacious antitumor agents. Over the last decade, considerable effort has
been expended in developing camptothecin (CPT) derivatives that selec-
tively target DNA topoisomerase I (TOP-I) (1). The prodrug irinotecan
(CPT-11) is approved for treatment of colon carcinoma and has demon-
strated significant activity against numerous other cancers in adults and
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children. Topotecan is approved for treatment of platinum- or taxane-resis-
tant ovarian carcinoma and has demonstrated broad-spectrum activity (2).
Other analogs are in clinical development, such as D5198f and the
homocamptothecins and liposomal formulations of CPT derivatives, and
offer the potential for prolonged plasma exposures.
Agents targeting TOP-I in clinical trials have proceeded through the
preclinical stages of identifying cytotoxic potency and confirmation of in
vivo antitumor activity. Acceptable toxicity in rodents and other species, as
mandated by regulatory agencies, had been studied before clinical evalua-
tion. CPTs have demonstrated remarkable activity against animal models
(3). However, less dramatic clinical activity has been reported, resulting in
the discontinuation of at least one agent, 9-aminocamptothecin (9-AC).
In this review, we examine this preclinical-clinical interface with respect
to understanding the value and limitations of preclinical models. Hopefully,
lessons learned regarding development of camptothecins can be applied to
the future development of drugs that induce cytotoxicity through their inter-
actions with TOP-I. This article will focus on preclinical models used to
assess antitumor activity and toxicity for TOP-I–targeted drugs and how
information derived from valid models may be used to direct the design of
clinical trials.
2. EARLY STUDIES
CPT was studied extensively in the Cancer Chemotherapy National Ser-
vice Center of the National Cancer Institute during the 1960s. It was formu-
lated in carboxymethylcellulose and administered by intraperitoneal (ip)
injection using the Walker 256 rat carcinosarcoma model as the test system.
Relative to other drugs evaluated, camptothecin had relatively poor activity
(4). However, the sodium salt of CPT demonstrated significant activity in
increasing survival time in several lymphocytic leukemias (5). Based on a
lack of cross-resistance to dichloromethotrexate, BCNU, cytosine arabino-
side, 6-mercaptopurine, and other agents, it was proposed that CPT had a
novel mechanism of action. In contrast to the significant activity observed
in these preclinical models, CPT, evaluated as the sodium salt, was found
to be ineffective in patients with advanced disseminated melanoma or gas-
trointestinal malignancies (6,7). Severe toxicities included myelo-suppres-
sion, vomiting, diarrhea, and hemorrhagic cystitis and resulted in the
discontinuation of the clinical trial of sodium CPT. Other studies in China,
however, demonstrated activity of 10-hydroxycamptothecin in treatment of
head-and neck-and bladder cancers (reviewed in ref. 8).
Studies by the Liu laboratory defined TOP-I as the target for CPT and the
observation that the CPTs caused trapping of TOP-I on DNA and induced
single-strand breaks (9,10) served as an impetus to reexplore this class of
agent. Although CPT is frequently referred to as an “inhibitor” of TOP-I, it
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actually functions to convert this cellular enzyme into a cellular toxin (11).
CPTs inhibit the religation step, effectively trapping covalently linked TOP-
I on DNA after a single-strand nick has been made by the enzyme. In cells
replicating DNA, this could result in a collision between an advancing
replication fork and the covalently linked enzyme-DNA complex, leading
to replication fork stalling or a double-strand DNA break. The mechanism
leading to cell death remains to be characterized, although it is believed that
double-strand DNA breaks can initiate a cascade leading to apoptosis. Thus
increased levels of TOP-I would favor increased formation of DNA–TOP-
I–drug complexes, which would increase the probability of a collision with
the advancing replication fork and the generation of DNA damage. In the
absence of DNA replication, the reversibly stabilized DNA–TOP-I covalent
complexes are not toxic, unless suprapharmacological drug concentrations
are used. Based on the mechanism of action, one would anticipate predomi-
nantly or exclusively S-phase cells would be sensitive to the CPTs (12).
Because many human cancers are characterized by having relatively low
growth fractions, protracted infusions or repeated exposures to drug over a
long period should optimize cell killing.
3. RODENT TUMOR MODELS
Syngenic transplanted rodent tumors have been used as the primary in
vivo screen for the activity of the CPT analogs. For leukemic models, such
as L1210 or P388, tumor cells are inoculated to the peritoneal cavity, and
drugs are administered ip. End points for these experiments are the drug-
induced increase in lifespan (ILS). Thus with increasing drug dose there is
an increase in lifespan until ILS is reduced because of drug induced toxicity.
These models are valuable in determining differences in efficacy between
analogs. Although such tests have been described as “in vivo test tubes,” an
objective of such screens is to avoid elimination of active compounds (i.e.,
false negatives).
In developing a CPT derivative at SmithKlineBeecham, several in vivo
criteria were established for selecting analogs for further development.
These included (1) being as active as CPT in a panel of preclinical models
and (2) minimizing the requirements for camptothecin as a starting mate-
rial—therefore, the analog was required to demonstrate potency in vivo
(i.e., a maximally tolerated dose, MTD) at similar or lower levels than
CPT (8). The analog 9-dimethylaminomethyl, 10-hydroxycampto-thecin
(topotecan) demonstrated superior ILS in mice bearing L1210 leukemia
compared with that achieved by camptothecin at their respective MTD (173
± 16 versus 118 ± 6% ILS).
For reasons given previously, protracted therapy with TOP-I inhibitors
theoretically should prove most efficacious. Thus, assuming reasonable
oral bioavailability, oral administration may prove to be most practical in
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therapy of human cancer. Secondary evaluation of topotecan compared the
efficacy of oral and intravenous (iv) administered drug in syngeneic mice
bearing (1) advanced systemic (iv inoculated) L1210, (2) advanced sys-
temic (iv inoculated) Lewis lung carcinoma,(3) subcutaneously implanted
Lewis lung carcinoma, (4) systemic (iv) B16 melanoma, and (5) ip implanted
M5076 reticulum cell sarcoma (13). Drug was administered every 3 hours
four times per day at 4- or 7-day intervals. Orally administered topotecan
was comparable in efficacy to parenteral treatment in four of five tumor
models tested. The M5076 sarcoma implanted ip responded to topotecan
administered ip or subcutaneously, but not when given orally.
Irinotecan (CPT-11; 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbo-
nyloxy-(20S)camptothecin) is a prodrug activated in rodents by plasma
carboxylesterases and has been extensively studied in syngenic tumors (14–
16). Irinotecan demonstrated significant activity by both parenteral and oral
routes against disseminated models, including the intravenous inoculation
of the highly metastatic B16-F10 melanoma and the spontaneous metastases
from subcutaneous implants of murine colon 26. The most comprehensive
study reported (16) evaluated irinotecan in 10 murine tumors and 1 human
xenograft. All 11 tumors responded to irinotecan, with 8 of them being
responsive at the Decision Network-2 level (in which treated/control vol-
umes were <10%), the criteria used by the National Cancer Institute to
justify further development. This work also showed no cross-resistance in
vivo in P388/vincristine leukemic cells resistant to vincristine and in human
breast carcinoma cells selected for resistance to docetaxel (Taxotere). Thus
rodent models indicate that camptothecins have significant antitumor effi-
cacy. However, rodents appear to be highly resistant to the toxic effects of
CPTs. For example, pharmacokinetic data showed that plasma concentra-
tions and exposures of SN-38 (7-ethyl,10-hydroxy-(20S)camptothecin), the
active metabolite of irinotecan, were significantly higher in mice than can
be achieved in patients. Although this problem is not unique to CPTs, it is
particularly problematic to irinotecan, because metabolism in mice is very
different from that in humans.
4. HUMAN XENOGRAFT MODELS
Since the early 1980s, human tumor xenografts grown in immune-
incompetent mice have to a large extent replaced transplantable syngenic
animal models. There remains debate over the predictive value of these
tumor models, because there was poor correlation between drug activity
against specific tumor types in mice and comparable tumor histologies in
clinical trials (17). In contrast, our experience using models of pediatric
solid tumors have been highly predictive in identifying agents active against
specific tumor types (18,19). The minimum requirement for validation of
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these models is that they should parallel the chemosensitivity-chemoresis-
tance profile of the clinical disease. Thus one would anticipate colon car-
cinomas would be less sensitive to chemotherapeutic agents than, for
example, pediatric rhabdomyosarcoma.
The most frequent approach taken is to heterograft surgical specimens of
tumor into mice that are congenitally immune deficient (athymic nude mice
or severe combined immunodeficiency mice) or mice that have been immune-
deprived to prevent graft rejection. Alternatively, cells initially propagated in
vitro from human tumors may be injected into these mice subcutaneously,
or iv, if disseminated disease is required. In certain circumstances (for
example, evaluation of brain tumors), it may be important to assess the
preclinical activity of a new drug under conditions that closely mimic the
clinical situation, in which case the development of orthotopic models can
be attempted by injecting cells into the analogous site within the host.
However, conditions for tumor growth in the mouse may differ from patients
and differences in drug disposition and metabolism in the mouse may signifi-
cantly influence tumor responses. Thus orthotopic models still have intrin-
sic limitations characteristic of other preclinical in vivo models. Several
lines representing a tumor type are generally required to accurately recapitu-
late the clinical situation and to conduct “preclinical phase II evaluation.” We
have used six tumor lines per tumor “model” (e.g., rhabdomyosarcoma, neu-
roblastoma). However, the exact number that accurately predicts clinical
response rates has not been determined and may require at least 10 tumors
per histiotype. In developing topotecan for the treatment of neuroblastoma,
we found that a daily systemic exposure to 100 ng/hour/mL topotecan lac-
tone gave objective regressions in four of six neuroblastoma xenograft
models. Interestingly, targeting the same exposure using the same schedule
of drug administration in children with stage IV neuroblastoma yielded a
response rate of approximately 60%.
The initial study by Giovanella and colleagues (3) demonstrating the
curative activity of 9-AC in chemorefractory colon cancer xenografts served
to focus considerable attention on this class of anticancer agent (3). Subcu-
taneous administration of drug  was highly active, whereas subsequent stud-
ies with iv administration were relatively disappointing. Significant
antitumor activity of camptothecin analogs has been confirmed using an
extensive panel of human tumor xenografts possessing a broad pattern of
biological properties and chemosensitivities (20–34) (Table 1). In contrast,
standard agents used for clinical treatment of the appropriate tumor type,
showed considerably less activity. 9-AC induced complete remissions in
mice bearing xenografts of colon adenocarcinoma and malignant mela-
noma BRO xenografts. 9-Nitrocamptothecin (rubitecan), is converted to 9-
AC and is currently under clinical investigation. 9-Nitrocamptothecin
demonstrated superior therapeutic efficacy compared with 9-AC and CPT
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in a large number of human xenograft models (21). Topotecan also demon-
strated good antitumor activity when administered iv, ip, and orally against
xenografts derived from various childhood solid tumors; of note topotecan
induced a high percentage of complete regressions in rhabdomyosarcomas,
neuroblastomas, and some brain tumors. Clinical studies support the predic-
tive value of these models. Clinically, topotecan has elicited high response
rates in rhabdomyosarcoma (35), neuroblastoma (approximately 60%), and
medulloblastoma (approximately 35%). In contrast, reduced activity was
found against colon carcinoma xenografts (22).
Irinotecan was a highly efficacious analog in preclinical studies and
currently is the “gold standard” against which new analogs are compared.
When administered by iv, ip, or oral routes, irinotecan showed substantial
activity against a broad spectrum of human tumor xenografts, including
human cancer xenograft lines unresponsive to many cytotoxic agents. High
cure rates were obtained against MX-1 mammary tumor, rhabdomyosarco-
mas, neuroblastomas, colon cancers, and brain tumors. Activity was also
retained against tumors selected for resistance to topotecan, vincristine,
melphalan, busulphan, procarbazine, and cyclophosphamide. As mentioned
previously, mice readily activate irinotecan to SN-38, and plasma systemic
exposure to SN-38 in mice greatly exceeds that achieved in patients. Thus
exposures to SN-38 associated with tumor regressions in mice may be far
in excess of exposures achievable in patients (discussed in Section 5.).
Two water-soluble analogs of CPT, GI147211 and GI149893 (10,11-
methylenedioxy, 7-substituted compounds), have been assessed in preclini-
cal models of colon and mammary carcinoma. Antitumor effects were dose-
and schedule-dependent, with a greater reduction in tumor volume achieved
by protracted dosing. Concurrent experiments demonstrated that these
agents were more effective than topotecan in suppressing tumor growth,
although optimal schedules for topotecan were not compared in these stud-
ies (27). As a liposomal formulation, GI147211 (designated NX211) has
demonstrated good antitumor activity against more than 20 lines of tumor
xenografts and yielded with minimal toxic effects.
Alternatively, it has been proposed that hydrophobic CPTs may have
greater E-ring stability, and hence may exert longer plasma exposures of the
lactone form. 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin (Karenit-
ecin) is under clinical development, as are other water-insoluble derivatives
such as DB-67. Homocamptothecins with an expanded E-ring are also in
clinical trials. Again, increased lactone stability was the rationale behind the
synthesis of these E-ring-modified agents.
For many of the experiments reported in Table 1, systemic exposures in
the mouse to lactone forms of the given CPT derivative far exceed exposures
that can be achieved in patients at tolerated dose levels. The data presented
demonstrate the relative sensitivity of a given tumor to a series of analogs
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administered to their MTD levels in the mouse. Such data may overestimate
the potential for activity in patients. Without knowing the relative toxicity–
systemic exposure relationship in humans, such data may have limited pre-
dictive value for selecting analogs for further development. Although
determination of the therapeutic efficacy in murine models serve as a poten-
tial criterion to select among analogs (assuming that mouse toxicity accu-
rately reflects dose limiting toxicity in patients), it may have relatively little
value in predicting clinical antitumor activity. For example, irinotecan admin-
istered daily for 10 days (MTD approximately 40 mg/kg/day) causes objec-
tive regressions in approximately 50% of colon carcinoma models (24).
However, we now know that a dose of 1.25 mg/kg to mice generates plasma
SN-38 exposures that are tolerated in patients when irinotecan is adminis-
tered on the same schedule. Thus evaluating the effect of camptothecin at
the MTD in mice significantly overpredicts clinical activity.
5. SCHEDULE-DEPENDENT ANTITUMOR ACTIVITY
Animal models have been useful for examining alternative schedules of
drug administration. Obtaining information about the schedule dependency
in relation to both the antitumor activity and host toxicity of an agent is one
of the goals of preclinical studies. TOP-I inhibitors are S-phase-specific
cytotoxins. It is assumed therefore that after a cytotoxic threshold is
achieved, exposure time, rather than further dose escalation, is the important
parameter for determining the tumor response. Consequently, protracted
drug administration could increase antitumor activity. Recent clinical data
support schedule-dependent activity (36), and additional clinical data, even
in phase I trials, show greater antitumor activity is associated with pro-
tracted schedules of administration (19,37).
The importance of scheduling was first reported by Kawato (20). Addi-
tional testing confirmed this observation (21–23). These studies showed
that, for similar total dosages, protracted schedules were more effective than
were more intense treatments of shorter duration. Several groups have
reported schedule-dependent activity of camptothecin analogs, although
this finding does not appear to have been used in design of the initial clinical
trials (38). Schedule-dependency is illustrated in Fig. 1, where the responses
of individual rhabdomyosarcoma Rh30 xenografts have been measured in
mice receiving drug vehicle (control) or topotecan treatment. Both treat-
ment groups received the same total dose of drug, the only difference being
that topotecan was either given over 5 days or 10 days. Clearly, topotecan
administered over 10 days was significantly more active than the same dose
given over 5 days. Also, in xenograft models drugs such as topotecan and
irinotecan appear to be “self-limiting.” Above some dose level, further
increases in dose per administration do not result in further antitumor activ-
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ity (21). Similar results have been obtained with 9-AC and other CPT
analoganalogs in various tumor models. Interestingly, administration of
irinotecan using the (day × 5) 2 schedule every 21 days has demonstrated
significant antitumor activity in a phase I clinical trial in children with
tumors resistant to conventional therapy (19,39).
6. MODELS OF RESISTANCE TO TOP-I INHIBITORS
Two CPT analogs, topotecan and irinotecan, are approved for treatment
of refractory ovarian carcinoma and 5-fluorouracil refractory colon carci-
noma, respectively. Thus new agents should demonstrate clear superiority
over these established drugs to justify full development. Irinotecan is highly
active against certain tumors that are intrinsically resistant to topotecan and
against some xenografts selected in situ for acquired resistance to topotecan
(24). Several cell lines selected for resistance to camptothecin have been
reported. In one line (CEM/C2), resistance is mediated by a mutation
(Asn722Ser) in TOP-I (39). In yeast, several mutations in TOP-I yield CPT
resistance (40). However, it is less certain in clinical tumors whether intrin-
sic or acquired resistance is the result of TOP-I mutations. Thus establishing
xenograft models from cell lines in which resistance is caused by mutant
enzyme may not necessarily recapitulate clinical resistance. At this time,
mechanisms conferring CPT resistance in clinical cancers remain
uncharacterized; however, the role of the breast cancer resistance–associ-
ated protein is associated in vitro with resistance to several camptothecin
analogs (41–44). Resistance to CPTs is undoubtedly complex, potentially
analog-specific, and involves mechanisms proximal to DNA damage (i.e.,
accumulation/efflux), at the target level (mutation or activity of TOP-I) or
distal to damage (repair processes). In several xenograft models, selection
in situ for resistance to topotecan did not result in cross-resistance to
irinotecan (24). However, relatively few models of acquired resistance to
CPT analogs have been reported. Relatively rapid development of an
irinotecan-resistant neuroblastoma xenograft (NB-1691/CPT) has been
reported (45). Resistant tumors were derived after only four rounds of treat-
ment/transplantation a stable irinotecan-resistant line was derived. This
tumor is partially resistant to topotecan. Although the mechanism of resis-
tance remains to be characterized, this tumor may represent a useful model
for identifying novel TOP-I-targeted agents with characteristics signifi-
cantly different from either irinotecan or topotecan.
7. TOXICITY
7.1. Hematopoietic Toxicity
The often dramatic preclinical activity of CPT analogs in xenograft
models contrasts with the clinical activity observed in many phase II stud-
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ies. As would be predicted from their S-phase activity, TOP-I inhibitors
cause dose-limiting toxicity to rapidly renewing tissues such as hematopoi-
etic tissues in humans and animals. Dose-limiting toxicity occurs at far
lower systemic exposures in humans than in mice. Humans can tolerate only
11% as much topotecan per day as mice. This differential may be greater for
irinotecan. Based on pharmacokinetic estimates of SN-38 systemic expo-
sure at the MTD in patients receiving irinotecan every 7 days, it was esti-
mated that the systemic exposure represented only 6% of the MTD in mice
(46). For myelosuppressive CPT analogs, failure to achieve drug exposures
in patients that are curative in the murine models might be due to greater
sensitivity of human myeloid progenitors. Using in vitro colony-forming
assays, Erickson-Miller et al. (47) showed that hematopoietic progenitors of
the myeloid lineage from humans, mice, and dogs exhibit differential sen-
sitivity to the CPTs. The toxicity of CPT analogs to human and animal
myeloid progenitors was quantified from the inhibition of marrow colony-
forming unit–granulocyte macrophage (CFU-GM) colony. CPT lactone,
topotecan, and 9-AC inhibited colony formation in a concentration-depen-
dent manner. These results suggest that, because of greater sensitivity of
the myelopoietic tissue, humans cannot tolerate exposures to CPTs that
are curative in murine models. Relative to human myeloid progenitors,
murine myeloid progenitors are relatively insensitive to all the compounds
examined. The differences between mice and humans are large. For example,
the concentration of topotecan causing a 50% reduction in CFUs was 46-fold
lower for human cells when compared with murine progenitors. This dif-
ferential was even greater (107-fold) for 9-AC (47). The susceptibility of
human CFU-GM to drug toxicity is more closely approximated by canine
than by murine CFU-GM. This finding explains, in part, why even subcu-
rative doses of CPTs may be severely myelotoxic in patients. The use of in
vitro systems for predicting human tissue toxicity may have wider applica-
tion to drug development (48,49).
7.2. Gastrointestinal Toxicity
Irinotecan, administered on most of the schedules evaluated clinically,
has been associated with an unanticipated and significant diarrhea. This is
characterized by the early onset of symptoms and is probably a consequence
of the acetylcholinergic activity of the bipiperidino side chain (50). This
toxicity is well controlled by atropine. However, delayed diarrhea is now
recognized as a dose-limiting toxicity of this compound (51). This toxicity
was not anticipated from studies in rodents, in which diarrhea was not
observed. Diarrhea may be caused by abnormalities of intestinal absorption
or secretion, increased peristalsis, or drug-induced epithelial damage. The
considerable interpatient variability in the severity of the diarrhea has made
it difficult to explain the mechanism of irinotecan-associated diarrhea. This
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toxicity, however, is not unique to irinotecan. Delayed-onset diarrhea is the
dose-limiting toxicity of topotecan administered orally to patients for 21
days. The etiology of this side effect of the CPTs is not yet clear, although
several animal models have been established that attempt to simulate
irinotecan-induced diarrhea.
7.2.1. MOUSE MODELS
Ikuno et al. (52) observed characteristic changes in the intestinal mucosa
of irinotecan-treated mice, including villous atrophy characterized by
marked shortening of the villi, epithelial vacuolation of the ileum (associ-
ated with increased apoptosis), and goblet cell hyperplasia in the cecum.
These structural and functional effects were postulated as the main causes
of irinotecan-induced diarrhea and resulted in malabsorption and hyperse-
cretion of mucin. Malabsorption in irinotecan-treated mice was thought to
be caused by villous atrophy after crypt damage and apoptosis of absorptive
cells in the small intestine. The goblet cell hyperplasia associated with
excessive production of mucin in the cecum could be another contributing
factor to the cause of diarrhea with irinotecan. A model of intestinal toxicity
has been developed in the mouse; this has been used to identify potential
modulators of irinotecan-induced diarrhea. Daily administration of very
high dose levels (100 mg/kg) of irinotecan to mice resulted in loss of villi,
epithelial vacuolation, decreased numbers of S-phase cells in the crypts,
increased apoptotic cells, and reduced numbers of lymphocytes in the lamina
propria. Oral administration of a synthetic bacterial lipopeptide, JBT 3002,
encapsulated in phospholipid liposomes prevented irinotecan-induced dam-
age to the intestinal epithelium and lamina propria (53). Similarly, dietary
supplementation with fish oil reduced gastrointestinal damage induced by
irinotecan (54).
7.2.2. RAT MODELS
Frequently, diarrhea is caused by the active secretion of electrolytes,
especially chloride ions, suggesting this toxicity is independent of the action
of irinotecan or the active metabolite, SN-38, on DNA–TOP-I. Relatively
high concentrations of irinotecan caused eicosanoid-mediated chloride secre-
tion in isolated rat colon (55). Irinotecan-induced diarrhea was characterized
in rats by assessing the relationship between intestinal toxicity and the
activity of enzymes involved in the major metabolic pathways of this drug
(56). In rodents, irinotecan is converted to its active metabolite SN-38 by
carboxylesterase; one possible mechanism for the diarrhea might include
the structural and functional injuries to the intestinal tract resulting from the
direct cytotoxic activity of the SN-38. Detoxification of SN-38 occurs by
liver glucoronidation and conjugated SN-38 is secreted into the bile and in
the feces. Conjugated metabolites may be further converted or processed to
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an active SN-38 by -glucuronidase of the microflora resident in the large
intestine. In this rat model, histological damage was most severe in the
cecum, with a markedly decrease in the size and number of crypts and
evidence of superficial mucosal erosion. The segmental differences in the
degree of damage showed good correlation with the -glucuronidase activ-
ity in the contents of the lumen, suggesting that this enzyme plays a key role
in intestinal toxicity induced by irinotecan. Intestinal tissue carboxylesterase
activity, which also converts irinotecan to its active form, showed poor
correlation to the degree of tissue damage. Administration of antibiotics to
sterilize the intestine exerted a protective effect against the diarrhea by
completely inhibiting the -glucuronidase activity of the intestinal flora
and, accordingly, the formation of active SN-38. Rustum and colleagues
(57) have also developed a rat model of irinotecan-induced gastrointestinal
toxicity. In their study, very high dose levels of irinotecan (150–200 mg/kg
daily × 3 iv) resulted in 86–100% lethality in treated animals and 93–100%
incidence of severe diarrhea, which was associated with serious damage to
the duodenal villi and colonic crypts. Interleukin-15 (100–400 μg/kg (3, 8,
and 11 doses ip) completely protected against irinotecan-induced delayed
diarrhea and lethality. The validity of these rodent models must, however,
wait for confirmatory results in other models and, ultimately, clinical trials.
7.2.3. HAMSTER MODELS
The hamster has also been proposed as a model for irinotecan-induced
intestinal toxicity (58). Female Syrian hamsters were dosed ip with
irinotecan (50 mg/kg/day) for 10 days and observed through day 20. By day
5, all treated animals had developed diarrhea and deaths occurred starting
on day 7. Histological examination revealed a time-dependent loss of struc-
tural integrity in the jejunal and ileal mucosa; the typical columnar morphol-
ogy of the epithelial cells was lost and the villi appeared corrugated. The
epithelium was thinned and vacuolated in the colon within the first 5 days
of treatment. Detection of proliferating cell nuclear antigen showed an
increase in the number of labeled epithelial cells and labeling intensity in
treated animals. The labeled cells were located further toward the tips of villi
compared with control animals. Increased levels of proliferating cell nuclear
antigen and loss of differentiation in cell morphology suggested that
irinotecan induces a cell-cycle block in S-G2, with subsequent loss of physi-
ologic function in hamster intestinal epithelium. Kobayashi et al. (59) have
also studied the effect of pH on uptake of irinotecan, SN-38 lactone, and SN-
38 carboxylate in isolated intestinal cells from Syrian hamsters. From these
studies, it is proposed that uptake of lactone is by passive diffusion, whereas
there may be an energy-dependent accumulation (transport) for carboxy-
late. Accumulation of irinotecan carboxylate showed saturation kinetics
with apparent Km approximately 50 μM in jejunal and ileal cells.
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8. INTERSPECIES DIFFERENCES THAT COMPLICATE
TRANSLATION OF PRECLINICAL RESULTS
8.1. Interspecies Differences in Drug Metabolism
and Disposition
CPTs have demonstrated greater activity against model tumors in rodents
than against tumors in patients. In part, this appears to be a consequence of the
greater tolerance of the toxic effects of these agents in mice than in humans.
Analysis of data from mice and rats showed that predicting clinical maxi-
mally tolerated doses for eight TOP-I inhibitors from rodent data would
result in starting clinical trials very close to, or at dose levels exceeding, the
human MTD (60). In contrast, initial starting doses based on canine data
would be safe. The plasma systemic exposures, expressed as an area under
the concentration-time curve, for irinotecan and its active metabolite SN-38
in mice (16,61) and patients (62–64) are presented in Table 2. To facilitate
comparison between schedules, systemic exposure has been expressed for
each course of therapy, usually in a 21-day time frame at the highest non-
toxic dose for mice and the MTD for humans. Not all investigators report
both the lactone and total drug, hence it is difficult to directly compare the
systemic exposure of irinotecan and SN-38 between studies. However, when
given once weekly in humans, the systemic exposure to irinotecan and,
particularly SN-38, is significantly greater in mice than in humans.
This raises the concern that studies with syngenic tumors or human
xenograft models in mice may overpredict the potential clinical utility
of this and other classes of anticancer drugs. For CPTs, the reasons for
the interspecies differences are not well understood. Rather than use the
mouse model to predict systemic drug exposures associated with toxicity,
we have determined the systemic exposure associated with antitumor effect
against the human tumor xenograft models. For a series of neuroblastoma
xenografts, the daily systemic exposure to topotecan that caused objective
regressions was determined when the drug was administered 5 days per
week for 2 consecutive weeks (33). Partial responses were achieved in each
of six independently derived neuroblastoma lines at a daily topotecan lac-
tone systemic exposure of 100 ng/mL/hour, whereas complete responses
were achieved in four tumor lines. The results of these studies define the
effective antitumor systemic exposure to the camptothecin analog. Current
data from our studies in children indicate that exposure of 100 ng/mL/hour
(achieved after a dose of 0.61 mg/kg in mice) results from a daily dose of
approximately 3 mg/m2 in children. For irinotecan, dose levels of approxi-
mately 1.25 mg/kg in mice yield SN-38 plasma systemic exposures achieved
at doses of 20–30 mg/m2 administered to children (19). This difference is a
consequence of very efficient activation of irinotecan by plasma carboxy-
lesterase in mice. In contrast, activation of irinotecan in humans is poor.
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Recently, a strain of mouse, designated Es1e, deficient in plasma esterases,
has been identified. Kinetic studies indicated that the activation of irinotecan
to SN-38 by Es1e mouse plasma in vitro is 600-fold less efficient, although
extracts from organs indicated no difference in drug metabolism as com-
pared with controls (65). It is proposed that the Es1e mouse may represent
a more representative model of irinotecan drug activation (66,67).
8.2. Protein Binding
Systemic exposure to CPT analogs represents total drug concentration,
which consists of both drug bound to plasma protein and unbound drug. For
drugs extensively bound to plasma proteins, such as SN-38, unbound drug
concentrations correlate best with the indices of pharmacologic effect.
Where there is significant interspecies variability in the plasma protein
binding, comparison between unbound drug concentrations and toxicity in
humans and animals may be more appropriate than the total drug concen-
tration. Interspecies differences in drug protein binding are seen with the
CPT analogs. CPT exists as a pentacyclic structure with a lactone moiety in
the terminal E-ring. When used against purified TOP-I, the presence of a
lactone ring is a structural requirement for activity. Factors influencing the
lactone-carboxylate equilibrium may therefore be important determinants
of drug activity. In addition to pH, presence of protein, particularly albumin,
has been shown to be important to the stability of the lactone moiety (68,69).
Human serum albumin has a marked preference for the carboxylate form of
CPT, greater than serum albumin from five other species. Thus binding of
the carboxylate to albumin drives the equilibrium away from the active
lactone form of the drug. Structural modifications to CPT, as seen with
irinotecan, SN-38, and topotecan, diminish the interspecies differences in
stabilization of the lactone. This is in contrast with 9-AC, in which the
marked interspecies difference in stabilization of the carboxylate form was
similar to that observed with CPT. Four hours after intragastric administra-
tion of camptothecin or 9-nitrocamptothecin, lactone forms compose 57–
81% and 47–95% of the total drug, in mouse plasma, respectively. In
contrast, the lactone composed only a minor component of total drug levels
in plasma from humans treated orally with either drug (70). This interspecies
variability in protein stabilization of the carboxylate form is important for
translation of data derived in rodents to clinical trials. These results also
illustrate the importance of determining the systemic exposure to lactone
forms of CPT analogs that induce objective regressions in xenograft mod-
els. This information may be valuable in understanding and designing phase
II clinical trials (71,72). Attempts to encapsulate and stabilize lactone forms
of CPTs may also increase the therapeutic utility of drugs such as CPT or
topotecan (73,74).
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9. FUTURE DIRECTIONS
Animal models, and human tumor xenografts in particular, have pre-
dicted dramatic clinical therapeutic activity of CPT drugs. Agents, such as
topotecan and irinotecan, are clearly active in several adult and childhood
cancers, as well as myelodysplastic syndromes. For analogs such as 9-AC,
clinical results have been quite disappointing. Retrospective analysis of
preclinical data for TOP-I inhibitors shows that such differences are caused
by interspecies differences in drug disposition and host tolerance. For CPTs,
mice tolerate significantly greater systemic exposure than can be achieved
in patients at tolerated levels of toxicity. Further, the remarkable schedule
dependency for antitumor activity seen in many preclinical models has not
been adequately addressed in the design of clinical trials. When response
rates for xenograft tumors are calculated for doses that yield clinically
achievable systemic exposures, these models rather accurately predict the
clinical results. Similarly, we would anticipate approximately 15–25% of
colon carcinoma xenografts demonstrating objective responses (50% vol-
ume regression) using doses of irinotecan that in mice yield clinically achiev-
able systemic exposures for SN-38. However, such information is not
available when selecting between analogs at a relatively early stage in
development. One way in which equi-efficacious analogs could be distin-
guished would be to introduce assays of differential species marrow toxicity
at an early stage in development. This may allow identification of analogs
with significant antitumor activity, but with little difference in species tox-
icity. Whether mouse transgenic models will obviate any of these issues
remains to be determined. These models may have the advantage of devel-
opment of spontaneous tumors, at more natural sites (e.g., medulloblastoma
in the cerebellum). Thus transgenics may represent specialized models for
drug evaluation. However, the problems of translating drug effects in rodent
to human remain.
The TOP-I-targeted agents in clinical investigation are mainly based on
a CPT structure. There are many more analogs in preclinical development.
One focus in developing novel CPTs has been on stabilization of the E-ring
lactone. This has been achieved by increasing the lipophilicity of CPTs by
substitution on the 7-position with bulky alkyl, alkylamino, and alkylsilyl
groups. A more novel approach has been synthesis of homocamptothecins,
in which a seven-membered lactone E-ring has far greater stability. Interest-
ingly, the homocamptothecin appears to change the sequence specificity of
the drug-induced DNA cleavage by TOP-I (75). However, differences in
lipophilicity are more likely to result in alterations in the pharmaceutical
properties of this class of agent, rendering longer plasma clearance times,
and potentially allowing greater systemic exposure to active forms of these
drugs. Because there are few clinical data to support the value of delivering
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CPTs by prolonged continuous infusion, it is unclear if analogs with greater
lactone stability will be more efficacious. Definitive activity in preclinical
models with intrinsic or acquired resistance to current CPTs would be
important in advancing such analogs to clinical testing. Perhaps of greater
interest will be development of novel topoisomerase inhibitors based on the
crystal structure of the DNA–TOP-I–DNA ternary complex.
New structures such as protoberberines (76), indolocarbazoles (rebec-
camycin analogs) (77), and lipophilic epipodophyllotoxins have emerged as
potential dual inhibitors of topoisomerases. Of particular interest is F11782,
an ethylidene glucoside ester of epipodophyllotoxin that putatively inhibits
the catalytic cycle of both type I and II enzymes, preventing their binding
to DNA (78). This agent has demonstrated significantly better activity
against both syngenic and xenograft tumor models than etoposide (79).
However, direct comparison with irinotecan and topotecan has not been
reported. Demonstration of activity of these newer inhibitors against CPT-
resistant tumors would be an exciting development. Development and char-
acterization of additional human tumor models resistant to CPTs would be
valuable.
The full curative/therapeutic potential of these drugs will not be realized
without compensating for the dose-limiting neutropenia and intestinal toxic-
ity. Thus approaches to reducing myelosuppression, through use of hemato-
poietic growth factors, reconstitution with peripheral blood cell progenitors,
or protecting marrow through transduction of CPT-resistant genes, appear
rational. Attempts to modulate intestinal toxicity through administration of
interleukin-15, or JBT 3002, or alkalinization of the intestinal lumen (80)
may allow increased dose intensity, or (rationally) more protracted courses
of treatment with these agents. Oral administration of topotecan and
irinotecan is limited by poor bioavailability. In children and mice, approxi-
mately 24% of topotecan and approximately 9% of irinotecan is absorbed.
Unabsorbed drug passing to the distal intestine may contribute to the
greater gastrointestinal toxicity observed in patients treated with oral
dosing. Recently, the use of agents that block the ABC-transporter, breast
cancer resistance protein ABCG2, have been shown to increase oral
bioavailability of CPTs (81). Such modulators may allow effective oral
therapy with these agents using protracted schedules of administration.
Validation of animal models of intestinal toxicity is important. Design of
clinical protocols that more accurately recapitulate optimal schedules and
drug exposures determined in xenograft models also seems appropriate with
these agents that are highly schedule-dependent in their antitumor activity.
Clearly an understanding of the biochemical or molecular events that deter-
mine such dramatic schedule dependency will help in more effective clini-
cal utilization of these agents, alone, or in combination with other cytotoxic
agents.
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